7-hydroxystaurosporine has been researched along with Skin Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwala, SS; Christensen, SD; Frankel, PH; Gandara, DR; Lara, PN; Li, T; Luu, T; Mack, PC; Margolin, KA | 1 |
| Akinaga, S; Akiyama, T; Okabe, M; Shimizu, M; Tamaoki, T | 1 |
| Arbuck, SG; Bauer, KS; Figg, WD; Fuse, E; Headlee, D; Jaken, S; Jing , X; Kuwabara, T; Lahusen, T; Lush, RM; Messmann, R; Murgo, A; Roberge, M; Sausville, EA; Senderowicz, AM | 1 |
2 trial(s) available for 7-hydroxystaurosporine and Skin Neoplasms
| Article | Year |
|---|---|
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; California; Cell Cycle; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Protein Kinase C; Protein Kinase Inhibitors; Skin Neoplasms; Staurosporine; Time Factors; Treatment Outcome | 2012 |
Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hyperglycemia; Hypotension; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Melanoma; Middle Aged; Nausea; Neoplasms; Skin Neoplasms; Staurosporine; Vomiting | 2001 |
1 other study(ies) available for 7-hydroxystaurosporine and Skin Neoplasms
| Article | Year |
|---|---|
Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle; Cell Cycle Proteins; Cell-Free System; Cyclin B; Cyclin B1; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Mitosis; Nocodazole; Phosphoprotein Phosphatases; Phosphorylation; Proteins; Skin Neoplasms; Staurosporine; Tumor Cells, Cultured; Tyrosine | 1999 |